Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trialPiero Ruggenenti, Giuseppe Remuzzi, Bogdan Ene‐Iordache et al.|The Lancet|2005Cited by 644
Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort StudyPaolo Cravedi, Piero Ruggenenti, Maria Chiara Sghirlanzoni et al.|American Journal of Nephrology|2011Cited by 71
Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case SeriesManuel Alfredo Podestà, Piero Ruggenenti|American Journal of Kidney Diseases|2023Cited by 33